Study reveals how our genes can alter action of the most commonly used Type 2 diabetes drug
- 12 August 2016
- Clinical Trials
Researchers in an international study have uncovered new genetic evidence of how the benefits of the world's most commonly used Type 2 diabetes drug may vary between individuals.
Metformin, a drug used by hundreds of millions of people with Type 2 diabetes worldwide, has been in use for over 50 years. It has been shown to protect against heart disease, and eye and kidney disease in people with Type 2 diabetes, and has also been shown to have benefits against cancer. Metformin is also undergoing new clinical trials to determine if it can promote healthy aging.